Genetic databases in pharmacogenomics: the Frequency of Inherited Disorders Database (FINDbase).

Methods Mol Biol

Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece.

Published: February 2014


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Pharmacogenomics studies how the variations of the individuals' genetic makeup are correlated with a person's response to certain drugs in relation to the therapeutic efficiency, clinical outcome, or even survival, and how they affect drug metabolism, transport, or clearance. Yet, since the incidence of these polymorphisms, being either single-point variations or small insertions/deletions, varies among different populations, a systematic collection and documentation of these variations is warranted, in order to facilitate implementation of pharmacogenomics in different populations. Here we review the existing electronic databases related to pharmacogenomics and pay particular attention in the description of the pharmacogenomics module Frequency of Inherited Disorders database (FINDbase), which documents curated allelic frequency data pertaining to 144 pharmacogenomics markers across 14 genes, representing approximately 87,000 individuals from 150 populations and ethnic groups worldwide. Long-term sustainability of these resources aims to contribute to the design, development, and implementation of pharmacogenomics testing towards the application of personalized approaches in medical treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-435-7_21DOI Listing

Publication Analysis

Top Keywords

databases pharmacogenomics
8
frequency inherited
8
inherited disorders
8
disorders database
8
database findbase
8
implementation pharmacogenomics
8
pharmacogenomics
7
genetic databases
4
pharmacogenomics frequency
4
findbase pharmacogenomics
4

Similar Publications

Background: Addictive disorders remain a global problem, affecting health, society and the economy. The etiopathogenesis of addictions, which have a multifactorial nature, is poorly understood, making it difficult to develop personalized treatment approaches. Of particular interest is the gene, which regulates serotonergic transmission.

View Article and Find Full Text PDF

Buprenorphine, a semi-synthetic opioid, is used to treat Opioid Use Disorder (OUD) and as an analgesic. Buprenorphine's benefits over other opioids include longer duration of action, lower abuse potential, and a ceiling effect to serious adverse effects such as respiratory depression. This is a literature review of gene variants affecting the pharmacokinetics and pharmacodynamics of buprenorphine from databases, such as PubMed.

View Article and Find Full Text PDF

This study aims to identify the primary active components of Danshen (Salvia miltiorrhiza) and explore the potential mechanisms underlying its therapeutic effect on Kawasaki disease (KD). Active components of Danshen and their action targets were screened using traditional Chinese medicine systems pharmacology and SwissTargetPrediction databases. KD-related targets were retrieved from Online Mendelian Inheritance in Man, Pharmacogenomics Knowledge Base, and GeneCards databases.

View Article and Find Full Text PDF

Variations in drug-metabolizing enzymes and transporters are associated with adverse drug reactions (ADRs). ADRs to cancer drugs can differ among populations owing to environmental and genetic differences. Due to limited resources and prohibitive costs associated with drug development, African countries rely on cancer drugs developed from non-African genetic backgrounds.

View Article and Find Full Text PDF

Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis.

Eur Neuropsychopharmacol

August 2025

Outpatient Clinic Pharmacogenetics, Parnassia Psychiatric Institute, Amsterdam, the Netherlands; Department of Psychological Medicine Institute of Psychiatry, Psychology and Neuroscience- King's College London, London, UK; St. John's National Academy of Health Sciences, Bangalore, India.

We conducted a systematic review and meta-analysis to estimate the efficacy of pharmacogenetic (PGx)-guided antidepressant treatment compared to treatment as usual (TAU) on functional outcomes and quality of life (QoL) in people with anxiety and affective disorders. A PRISMA-compliant systematic search was performed up to 26/06/2025 to identify relevant prospective, randomised controlled trials (RCTs) in seven databases. The revised tool for Risk of Bias (RoB2) was used to assess the methodological qualities of the included studies (PROSPERO CRD42024518683).

View Article and Find Full Text PDF